Botulinum Toxin A for Chronic Pelvic Pain
Author Information
Author(s): Melle A. Spruijt, Wenche M. Klerkx, Kim Notten, Hugo van Eijndhoven, Leonie Speksnijder, Manon H. Kerkhof, Kirsten B. Kuivers
Primary Institution: Radboud University Medical Center
Hypothesis
Women with chronic pelvic pain receiving Botulinum Toxin A injections in combination with pelvic floor muscle therapy will experience greater reductions in pain and improvements in quality of life compared to those receiving placebo injections with pelvic floor muscle therapy.
Conclusion
The results from this study do not support the use of Botulinum Toxin A injections in the management of chronic pelvic pain in women.
Supporting Evidence
- 33% of women in the BTA group reported at least a 33% reduction in pain.
- 17% of women in both groups reported being 'much better' or 'very much better'.
- Pelvic floor resting activity decreased significantly after BTA treatment compared to placebo.
Takeaway
The study tested if a special injection could help women with pelvic pain feel better, but it didn't really work better than a fake injection.
Methodology
Participants received either Botulinum Toxin A or placebo injections into the pelvic floor muscle, followed by pelvic floor muscle therapy sessions.
Potential Biases
Envelope randomisation may introduce bias, although baseline characteristics were similar between groups.
Limitations
The study was affected by the COVID-19 pandemic, which led to cancellations of follow-up visits and potential placebo effects.
Participant Demographics
The study included 94 women with chronic pelvic pain, median age 47 years, predominantly Caucasian.
Statistical Information
P-Value
0.19
Confidence Interval
95% CI 0.72–4.90
Statistical Significance
p=0.19
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website